High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: Correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features

Journal of Thoracic Oncology

Volumn 7, Issue 2, 2012, Pages 323-330

  Sun, Ping Li ^a   Seol, Hyesil ^b   Lee, Hyun Ju ^c   Yoo, Seol Bong ^a   Kim, Hyojin ^a   Xu, Xianhua ^a   Jheon, Sanghoon ^a   Lee, Choon Taek ^a   Lee, Jong Suk ^a   Chung, Jin Haeng ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Adenocarcinoma; EGFR mutation; Histology; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ACINAR CELL CARCINOMA; ADULT; ARTICLE; CLINICAL FEATURE; EXON; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; SOLID TUMOR; WORLD HEALTH ORGANIZATION;

EID: 84862779691     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182381515     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-299. (Pubitemid 41379403)
3. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
4. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54:12-27.
5. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
6. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008;5:209-217.
7. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109. (Pubitemid 41095044)
8. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas: significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009;63:235-240.
9. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26: 1472-1478.
10. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004;10:7311-7317. (Pubitemid 39487720)
11. Saijo N, Kenmotsu H. Recent development of molecular-targeted drugs in lung cancer. Intern Med 2010;49:1923-1934.
12. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005;128:317-321.
13. Inamura K, Ninomiya H, Ishikawa Y, et al. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med 2010;134:66-72.
14. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29:633-639. (Pubitemid 40577873)
15. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010;29:23-36.
16. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
17. Sonobe M, Manabe T, Wada H, et al. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005;93:355-363. (Pubitemid 43080038)
18. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007;9:320-326. (Pubitemid 47305068)
19. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006;125:860-865. (Pubitemid 43801536)
20. Lee HJ, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 2010;68:375-382.
21. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008;10: 242-248. (Pubitemid 351692167)
22. Yoo SB, Chung JH, Lee HJ, et al. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J Thorac Oncol 2010;5:964-969.
23. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
24. Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007;13: 5763-5768. (Pubitemid 47583901)
25. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203.
26. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11:2106-2110. (Pubitemid 40490166)
27. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923. (Pubitemid 39665498)
28. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
29. Han SW, Kim TY, Lee KH, et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer 2006;54:201-207.
30. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008;99:303-308. (Pubitemid 351228484)
31. Westra WH. Early glandular neoplasia of the lung. Respir Res 2000;1: 163-169.
32. Jian Z, Tomizawa Y, Yanagitani N, et al. Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes. Pathol Int 2005;55:619-625. (Pubitemid 41726945)
33. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972-2977.
34. Nakano H, Soda H, Takasu M, et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008;60:136-140. (Pubitemid 351434456)
35. Sakurada A, Lara-Guerra H, Liu N, et al. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008;3:527-529. (Pubitemid 351630282)